🇺🇸 FDA
Pipeline program

80 mg DR-6MP

C2/13/DR-6MP-02 EXT

Phase 2 small_molecule terminated

Quick answer

80 mg DR-6MP for Crohn's Disease is a Phase 2 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Crohn's Disease
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials